Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-06-24 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Simplified Report on Changes in Shareholding". It details the change in shareholding percentage of CLSA Asset Management Limited in Shenzhen Salubris Pharmaceuticals Co., Ltd. due to a non-public issuance of shares by the company, resulting in passive dilution of the shareholding percentage from 5% to 4.69%. The document includes detailed information about the shareholder, the nature of the shareholding change, legal references to securities laws, and declarations about the accuracy and completeness of the information. It is a formal disclosure of a change in major shareholding but does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, nor an earnings release or management report. It is not a proxy statement or voting result announcement. The document fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length (6369 characters) and content confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2021-06-24 Chinese
关于持股5%以上股东持股比例被动稀释超过1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder holding more than 5% whose shareholding percentage was passively diluted by more than 1% due to a non-public issuance of shares by the company. It includes details about the shareholder, shareholding changes, and compliance statements. The document is a formal disclosure of a change in major shareholding levels, not a full financial report or other types of filings. It matches the definition of a Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming MRQ classification.
2021-06-24 Chinese
关于技术转让协议的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a technology transfer agreement, including contract signing, breach, and unilateral termination by the company. It contains no financial statements or detailed financial data but rather informs shareholders and the public about a contractual dispute and related risks. The document is relatively short (883 characters) and serves as a regulatory disclosure of a material event affecting the company. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the contract status. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-06-24 Chinese
关于部分药品拟中选全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the company's proposed selection of certain pharmaceutical products in a national centralized drug procurement. It details the products, prices, supply regions, and procurement terms. The document is an announcement of a business development event related to product procurement and market expansion, not a financial report, earnings release, or regulatory filing. It does not contain financial statements, management discussion, or voting results. It is a typical corporate announcement about product procurement outcomes and related business impact. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2021-06-24 Chinese
关于设立募集资金专户暨签订募集资金三方监管协议、四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the establishment of a special account for raised funds and the signing of three-party and four-party supervision agreements related to the management and use of these funds. It details the approval by the China Securities Regulatory Commission for a non-public stock issuance, the amount raised, the use of funds, and the regulatory agreements signed to supervise the funds. There are no financial statements or detailed financial performance data presented. The document is a formal announcement about fundraising and regulatory compliance related to capital management, not a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3632 characters, which is consistent with an announcement rather than a full report.
2021-06-22 Chinese
关于控股股东部分股份质押及解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the pledge and release of shares by its controlling shareholder. It details the number of shares pledged and released, the proportion of shares involved, and confirms that the pledge does not affect control or involve performance compensation obligations. The document is structured as a disclosure announcement about share pledging activities, including tables of share quantities and pledge details. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of share pledge and release events. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledging activities that do not fit into more specific categories like Major Shareholding Notification or Transaction in Own Shares, since it concerns pledge status rather than ownership changes or share buybacks. The document length is short (2221 characters), and it is a standalone announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-06-22 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.